Please see enclosed annexure

July 24, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir / Madam, Sub: Investors / Analysts Presentation Please find enclosed the presentation to the Investors / Analysts on the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2026, for the Investors / Analysts call scheduled on July 24, 2026 at 05.00 p.m. (IST), which was already intimated on July 09, 2026. The presentation is also being uploaded on the website of the Company i.e., www.lauruslabs.com. This is for your information and records. Thanking you, Yours sincerely, For Laurus Labs Limited G. Venkateswar Reddy Company Secretary & Compliance Officer Encl: A/a Q1-FY 2027 20 Years Financial logo Results 24/07/2026 © 2026 Laurus Labs Ltd. Agenda 1 Q1 - FY 2027 Corporate Overview 2 Q1 - FY 2027 Financial Overview 3 Q1 - FY 2027 Business Review & Strategy © 2026 Laurus Labs Ltd. Q1 -FY27 Results Presentation 24/07/2026 2 Safe Harbor Statement This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations. These factors include, but not limited to: 1) Change in the General market and macro-economic conditions for key global markets where we operate, 2) Governmental and regulatory trends, 3) Allocations of funds by the Governments in our key global markets, 4) Successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 5) Movements in currency exchange and interest rates, 6) Increase in the competitive pressures and Technological developments, 7) Changes in the financial conditions of third parties dealing with us, 8) Changes in laws and regulations that apply to our customers, suppliers and Pharmaceutical industry. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Laurus Labs Limited may vary materially from those described in the relevant forward-looking statements The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise. This presentation is strictly confidential and may not be copied or disseminated, reproduced, re-circulated, re-distributed, published or advertised in any media, website or otherwise, in whole or in part, and in any manner or for any purpose without written approval from Laurus Labs Limited. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue ofCapital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information fromthis presentation shall be governed by the laws of India and only the courts in Telangana, India, and no other courts, shall have jurisdiction over the same. © 2026 Laurus Labs Ltd. Q1 -FY27 Results Presentation 24/07/2026 3 Corporate Overview Q1 - FY 2027 Executive Summary • Continued strong Q1 performance ; ₹ 2,026 Cr Revenue with 29% growth • Strong growth in CDMO revenue driven by commercial projects supplies and steady momentum in Affordable Medicines segment • ₹ 644 Cr EBITDA with margins of 31.8%, increased by 7.0% pts, contributed by enhanced CDMO revenue and operational leverage • Gross margins expansion of over 3.3% pts to 62.7% on healthy business segment mix • Continued investment into manufacturing network expansion and niche capabilities with overall CAPEX at 19% of sales © 2026 Laurus Labs Ltd. Q1 -FY27 Results Presentation 24/07/2026 5 Continue to drive Growth CAPEX projects across portfolio and technologies Q1 CAPEX : ₹394 Cr FY22-27* CAPEX : ₹4700+ Cr • >85% Growth CAPEX; Building diversified (19% of Revenue) (16% of Revenue) portfolio across technologies • Healthy order book, internal pipeline and key By Customers Portfolio • Key projects in API, Formulations, Peptides, Fermentation, Gene Therapy and Antibody Drug Conjugates ATR progress (FY22-27*) • Q1 CAPEX at ₹ 394 Cr; 19% of Revenue 5-Yr average >1.0x 1.0x • ATR improving in medium-term in-line with 0.9x 5 year Long term average FY22 FY25 FY26 1Q FY27 Medium term * Cumulative addition including CWIP, Land, ETP and plant maintenance till June 2027 © 2026 Laurus Labs Ltd. Q1 -FY27 Results Presentation 24/07/2026 6 9 4 % C D M O 1 7 % 8 6 % 8 3 % I/ C P E X Strengthening Integrated manufacturing network & Capabilities to enable customers Small Molecules API & FDF R & D Fermentation CGT & ADC Unit 1 & 3, Vizag +3600 kL Unit 6, Vizag 1476 kL R&D 1 & Kilo lab, Hyderabad LB-1 & LB-2, Bangalore CAR-T unit-1, Mumbai +240 kL +600 treatment Unit 5, Vizag 161 kL Unit 10, Vizag (new site) R&D 2, Hyderabad Unit 7, Vizag (new site) LSPL 2, Vizag +400 kL LB-4, Vizag +400 kL^ (new site) CAR-T unit-2, Mumbai +2500 treatment Unit 2, Vizag +12bn units LSPL 4, Vizag +300 kL Gene Therapy/ADC, Unit 4, Vizag +2000 kL KRKA JV site, Hyderabad Hyderabad (new site) Enabling Technology Platforms High potent Flow technology Continuous manufacturing Peptides Bio-catalysis Trickle bed hydrogenation Spray Drying 6 Research & Development assets 15 Manufacturing assets 8300 kL 12 billion 240 kL 1570 56000 m2 Fermentation API capacity FDF capacity Fermentation capacity Research Scientists GLP lab facility Site under expansion or construction ^ Capacity proposed in Phase 1 © 2026 Laurus Labs Ltd. Q1 -FY27 Results Presentation 24/07/2026 7 Confirming SBTi targets and consistent ESG recognition Scope 1 + 2 Scope 3 • >50% electricity from renewable source (Wind+Solar) by 2031 via PPA for all sites SBTi roadmap • Near term GHG reduction target towards GHG -42% -51.6% validated by SBTi reduction target 2031 • Sustainable Procurement code inline with ISO 20400:2017 principles Absolute reduction by Intensity reduction per ₹ by established 42% until FY31 (vs. FY25) 51.6% until FY31 (vs. FY25) © 2026 Laurus Labs Ltd. Q1 -FY27 Results Presentation 24/07/2026 8 & P G lo b S c o r e Target Target Key recognitions for our ESG programs Financial Overview Q1 - FY 2027 1Q FY27: Highest Revenue, EBITDA and Profit momentum 1Q FY27 Financial Summary Comments [₹Crore] 4QFY26 1QFY27 1QFY26 Y-o-Y Q-o-Q • Revenue : ₹ 2,026 Cr, increased 29% primarily driven by robust CDMO growth supported by sustained Affordable Medicine business (led by FDF) Revenue 1,812 2,026 1,570 29% 12% • Gross Margins : 62.7%, increased by 330 bps on better divisional mix Gross Margins 61.4% 62.7% 59.4% +3.3% +1.3% • EBITDA : ₹ 644 Cr, increased by 66% Y/Y EBITDA 523 644 389 66% 23% • EBITDA Margins : 31.8%, increased 700 bps Y/Y, due to favorable product mix % to Revenue 28.9% 31.8% 24.8% +7.0% +2.9% and improving operational leverage Net Profit 2 [Showing first 8,000 characters — download PDF for full document]